These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 21703756)

  • 1. Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage.
    Mink S; Muroi C; Seule M; Bjeljac M; Keller E
    Clin Neurol Neurosurg; 2011 Oct; 113(8):644-8. PubMed ID: 21703756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved seizure control by alternating therapy of levetiracetam and valproate in epileptic rats.
    van Vliet EA; Edelbroek PM; Gorter JA
    Epilepsia; 2010 Mar; 51(3):362-70. PubMed ID: 19674045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute seizures due to a probable interaction between valproic acid and meropenem.
    Coves-Orts FJ; Borrás-Blasco J; Navarro-Ruiz A; Murcia-López A; Palacios-Ortega F
    Ann Pharmacother; 2005 Mar; 39(3):533-7. PubMed ID: 15701769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs).
    Stepanova D; Beran RG
    Seizure; 2014 May; 23(5):371-6. PubMed ID: 24630809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model.
    Wojda E; Wlaz A; Patsalos PN; Luszczki JJ
    Epilepsy Res; 2009 Oct; 86(2-3):163-74. PubMed ID: 19596559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epileptic seizures caused by low valproic acid levels from an interaction with meropenem.
    Fudio S; Carcas A; Piñana E; Ortega R
    J Clin Pharm Ther; 2006 Aug; 31(4):393-6. PubMed ID: 16882111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients.
    Spencer DD; Jacobi J; Juenke JM; Fleck JD; Kays MB
    Pharmacotherapy; 2011 Oct; 31(10):934-41. PubMed ID: 21950640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of concomitant administration of meropenem and valproic acid in an elderly Chinese patient.
    Gu J; Huang Y
    Am J Geriatr Pharmacother; 2009 Feb; 7(1):26-33. PubMed ID: 19281938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of levetiracetam in the treatment of Panayiotopoulos syndrome.
    García C; Rubio G
    Epilepsy Res; 2009 Aug; 85(2-3):318-20. PubMed ID: 19423296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levetiracetam as a treatment option in non-convulsive status epilepticus.
    Rupprecht S; Franke K; Fitzek S; Witte OW; Hagemann G
    Epilepsy Res; 2007 Mar; 73(3):238-44. PubMed ID: 17161587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy.
    Otoul C; De Smedt H; Stockis A
    Epilepsia; 2007 Nov; 48(11):2111-5. PubMed ID: 17651416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs.
    Ji-qun C; Ishihara K; Nagayama T; Serikawa T; Sasa M
    Epilepsia; 2005 Sep; 46(9):1362-70. PubMed ID: 16146430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of reproductive effects of levetiracetam and valproate studied in prepubertal porcine ovarian follicular cells.
    Taubøll E; Gregoraszczuk EL; Tworzydø A; Wójtowicz AK; Ropstad E
    Epilepsia; 2006 Sep; 47(9):1580-3. PubMed ID: 16981877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial.
    Bähr O; Hermisson M; Rona S; Rieger J; Nussbaum S; Körtvelyessy P; Franz K; Tatagiba M; Seifert V; Weller M; Steinbach JP
    Acta Neurochir (Wien); 2012 Feb; 154(2):229-35; discussion 235. PubMed ID: 21909835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of valproate, carbamazepine, and levetiracetam on the antioxidant and oxidant systems in epileptic patients and their clinical importance.
    Varoglu AO; Yildirim A; Aygul R; Gundogdu OL; Sahin YN
    Clin Neuropharmacol; 2010 May; 33(3):155-7. PubMed ID: 20502135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA).
    Stefan H; Wang-Tilz Y; Pauli E; Dennhöfer S; Genow A; Kerling F; Lorber B; Fraunberger B; Halboni P; Koebnick C; Gefeller O; Tilz C
    Epilepsia; 2006 Mar; 47(3):516-22. PubMed ID: 16529615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Encephalopathy induced by levetiracetam added to valproate.
    Bauer J
    Acta Neurol Scand; 2008 May; 117(5):374-6. PubMed ID: 18081909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
    Kerkhof M; Dielemans JC; van Breemen MS; Zwinkels H; Walchenbach R; Taphoorn MJ; Vecht CJ
    Neuro Oncol; 2013 Jul; 15(7):961-7. PubMed ID: 23680820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lacosamide Lowers Valproate and Levetiracetam Levels.
    Tountopoulou M; Weschke B; Kaindl AM
    Neuropediatrics; 2017 Jun; 48(3):188-189. PubMed ID: 28324910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage.
    Karamchandani RR; Fletcher JJ; Pandey AS; Rajajee V
    J Clin Neurosci; 2014 Sep; 21(9):1507-13. PubMed ID: 24919470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.